Annamaria Ruzzo

5PUBLICATIONS
7CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Oct 22, 2024
Clinical impact of TP53 functional mutations in patients with metastatic colorectal cancer treated with bevacizumab and chemotherapy.

Annamaria Ruzzo, Francesco Graziano, Silvia Palladino

|Jul 30, 2020
TP53 Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard Chemotherapy.

Francesco Graziano, Nicholas W Fischer, Irene Bagaloni

|May 07, 2020
Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab.

Annamaria Ruzzo, Francesco Graziano, Irene Bagaloni

|Feb 02, 2020
Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy.

Annamaria Ruzzo, Francesco Graziano, Francesca Galli

|Aug 10, 2019
Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy.

Annamaria Ruzzo, Francesco Graziano, Francesca Galli

Pageof 1

Frequent Collaborators

2 joint publications

Eliana Rulli

1 joint publications

Sara Lonardi

1 joint publications

Lorenzo Fornaro

1 joint publications

Michele Prisciandaro